주 메뉴 바로가기 본문 바로가기 하단 바로가기

Pipeline

We look for ways to promote health and happiness for all

Antibody Biosimilars

Celltrion will continue to blaze new trails and discover new opportunities.
Project INN Original Major Indications Status Clinical Info
CT-P39 Omalizumab XOLAIR® Asthma, Urticaria Phase3 외부링크연결
CT-P41 Denosumab

PROLIA®

Osteoporosis, Bone Loss Phase3 외부링크연결
CT-P43 Ustekinumab

STELARA

Psoriasis, Crohn's disease, Ulcerative colitis Phase3 외부링크연결
CT-P42 Aflibercept

EYLEA

Diabetic Macular Edema Phase3 외부링크연결
CT-P47 Tocilizumab

ACTEMRA

Rheumatoid arthritis Phase3 외부링크연결
CT-P53 Ocrelizumab

OCREVUS

Multiple sclerosis Phase3 외부링크연결
  • * Registered trademarks of reference products
  • XOLAIR® is a registered trademark of NOVARTIS
  • AVASTIN® is a registered trademark of GENENTECH
  • PROLIA® is a registered trademark of AMGEN
  • STELARA® is a registered trademark of JANSSEN
  • EYLEA® is a registered trademark of REGENERON and BAYER
  • ACTEMRA® is a registered trademark of CHUGAI SEIYAKU

New Antibodies

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-P27 Pandemic·Seasonal influenza Phase2

IMDs

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-G20 Cardiomyopathy Phase1